Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/29932
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.contributor.authorBuffels, R.-
dc.contributor.authorClinch, S.-
dc.contributor.authorKuhelj, R.-
dc.contributor.authorWei, W.-
dc.contributor.authorVermersch, P.-
dc.date.accessioned2019-11-12T13:31:32Z-
dc.date.available2019-11-12T13:31:32Z-
dc.date.issued2019-
dc.identifier.citationMULTIPLE SCLEROSIS JOURNAL, 25(S2), p. 824-825-
dc.identifier.issn1352-4585-
dc.identifier.urihttp://hdl.handle.net/1942/29932-
dc.description.sponsorshipSponsored by F. Hoffmann-La Roche Ltd; writing and editorial assistance was provided by Articulate Science, UK. B. Van Wijmeersch has received financial support/study grants and fees for speaking and serving on advisory boards from Bayer, Biogen, F. Hoffmann-La Roche Ltd, Genzyme/Sanofi, Merck Serono, Novartis and Teva.-
dc.language.isoen-
dc.publisherSAGE PUBLICATIONS LTD-
dc.subject.otherClinical Neurology; Neurosciences-
dc.titleOcrelizumab treatment satisfaction in patients with suboptimal response to previous disease-modifying therapies-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateSEP 11-13, 2019-
local.bibliographicCitation.conferencename35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS-
local.bibliographicCitation.conferenceplaceStockholm, SWEDEN-
dc.identifier.epage825-
dc.identifier.issueS2-
dc.identifier.spage824-
dc.identifier.volume25-
local.format.pages2-
local.bibliographicCitation.jcatM-
dc.description.notes[Van Wijmeersch, B.] Univ Hasselt, Overpelt, Belgium. [Van Wijmeersch, B.] Rehabil & MS Ctr Overpelt, Overpelt, Belgium. [Buffels, R.; Kuhelj, R.; Wei, W.] F Hoffmann La Roche Ltd, Basel, Switzerland. [Clinch, S.] F Hoffmann La Roche Ltd, Welwyn Garden City, Herts, England. [Vermersch, P.] Univ Lille, Lille, France.-
local.publisher.placeLONDON-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
dc.identifier.isi000485303103278-
item.fullcitationVAN WIJMEERSCH, Bart; Buffels, R.; Clinch, S.; Kuhelj, R.; Wei, W. & Vermersch, P. (2019) Ocrelizumab treatment satisfaction in patients with suboptimal response to previous disease-modifying therapies. In: MULTIPLE SCLEROSIS JOURNAL, 25(S2), p. 824-825.-
item.contributorVAN WIJMEERSCH, Bart-
item.contributorBuffels, R.-
item.contributorClinch, S.-
item.contributorKuhelj, R.-
item.contributorWei, W.-
item.contributorVermersch, P.-
item.fulltextNo Fulltext-
item.accessRightsClosed Access-
crisitem.journal.issn1352-4585-
crisitem.journal.eissn1477-0970-
Appears in Collections:Research publications
Show simple item record

Page view(s)

28
checked on Jul 31, 2023

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.